DE602005027322D1 - Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall - Google Patents
Verwendung von antikörpern gegen tweak zur behandlung von schlaganfallInfo
- Publication number
- DE602005027322D1 DE602005027322D1 DE602005027322T DE602005027322T DE602005027322D1 DE 602005027322 D1 DE602005027322 D1 DE 602005027322D1 DE 602005027322 T DE602005027322 T DE 602005027322T DE 602005027322 T DE602005027322 T DE 602005027322T DE 602005027322 D1 DE602005027322 D1 DE 602005027322D1
- Authority
- DE
- Germany
- Prior art keywords
- tweak
- modulate
- inhibit
- treatment
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04004094A EP1566636A1 (de) | 2004-02-23 | 2004-02-23 | Verwendung von Modulatoren und Inhibitoren von TWEAK zur Behandlung von neurologischen Zuständen |
PCT/EP2005/001921 WO2005080972A1 (en) | 2004-02-23 | 2005-02-23 | Use of tweak modulators and inhibitors for the treatment of neurological conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005027322D1 true DE602005027322D1 (de) | 2011-05-19 |
Family
ID=34707372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005027322T Active DE602005027322D1 (de) | 2004-02-23 | 2005-02-23 | Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP1566636A1 (de) |
JP (1) | JP2007532482A (de) |
KR (1) | KR20070029677A (de) |
CN (1) | CN1985169A (de) |
AT (1) | ATE504600T1 (de) |
AU (1) | AU2005214843A1 (de) |
BR (1) | BRPI0507959A (de) |
CA (1) | CA2558770A1 (de) |
DE (1) | DE602005027322D1 (de) |
EA (1) | EA200601547A1 (de) |
IL (1) | IL177285A0 (de) |
IS (1) | IS8540A (de) |
MX (1) | MXPA06009518A (de) |
NO (1) | NO20064293L (de) |
WO (1) | WO2005080972A1 (de) |
ZA (1) | ZA200606840B (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01007163A (es) | 1999-01-15 | 2002-03-27 | Biogen Inc | Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos. |
NZ548701A (en) | 2002-04-09 | 2008-03-28 | Biogen Idec Inc | Methods for treating tweak-related conditions |
AU2006214179A1 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
AU2011239311B2 (en) * | 2005-02-17 | 2014-05-22 | Biogen Ma Inc. | Treating Neurological Disorders |
ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
UA96416C2 (uk) | 2005-05-27 | 2011-11-10 | Байоджэн Айдэк Ма Инк. | Антитіло, яке зв'язується з tweak людини |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
EP1876448A1 (de) * | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Verfahren und analytische Reagenzien zur Medikamentidentifizierung mittels auf Thiazolidinedionen reagierenden Biomarkern |
EP2545938A1 (de) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutische Verwendung von Anti-TWEAK-Rezeptorantikörpern |
US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
US8609818B2 (en) | 2011-03-10 | 2013-12-17 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276110A (en) | 1978-11-30 | 1981-06-30 | Yardney Electric Corporation | Method of forming a separator integral with an electrode |
US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
MXPA01007163A (es) * | 1999-01-15 | 2002-03-27 | Biogen Inc | Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos. |
EP2260867A1 (de) * | 2000-09-14 | 2010-12-15 | Biogen Idec MA Inc. | TWEAK Rezeptoragoniste als antiangiogene Agenzien |
-
2004
- 2004-02-23 EP EP04004094A patent/EP1566636A1/de not_active Withdrawn
-
2005
- 2005-02-23 WO PCT/EP2005/001921 patent/WO2005080972A1/en active Application Filing
- 2005-02-23 CA CA002558770A patent/CA2558770A1/en not_active Abandoned
- 2005-02-23 AT AT05715497T patent/ATE504600T1/de not_active IP Right Cessation
- 2005-02-23 DE DE602005027322T patent/DE602005027322D1/de active Active
- 2005-02-23 CN CNA2005800056025A patent/CN1985169A/zh active Pending
- 2005-02-23 KR KR1020067019381A patent/KR20070029677A/ko not_active Application Discontinuation
- 2005-02-23 JP JP2006553571A patent/JP2007532482A/ja active Pending
- 2005-02-23 MX MXPA06009518A patent/MXPA06009518A/es not_active Application Discontinuation
- 2005-02-23 EP EP05715497A patent/EP1721157B1/de active Active
- 2005-02-23 BR BRPI0507959-4A patent/BRPI0507959A/pt not_active Application Discontinuation
- 2005-02-23 AU AU2005214843A patent/AU2005214843A1/en not_active Abandoned
- 2005-02-23 EA EA200601547A patent/EA200601547A1/ru unknown
-
2006
- 2006-08-03 IL IL177285A patent/IL177285A0/en unknown
- 2006-08-15 ZA ZA200606840A patent/ZA200606840B/xx unknown
- 2006-09-15 IS IS8540A patent/IS8540A/is unknown
- 2006-09-22 NO NO20064293A patent/NO20064293L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005214843A1 (en) | 2005-09-01 |
NO20064293L (no) | 2006-09-22 |
EP1721157A1 (de) | 2006-11-15 |
BRPI0507959A (pt) | 2007-07-17 |
IS8540A (is) | 2006-09-15 |
CN1985169A (zh) | 2007-06-20 |
KR20070029677A (ko) | 2007-03-14 |
EP1566636A1 (de) | 2005-08-24 |
EA200601547A1 (ru) | 2006-12-29 |
IL177285A0 (en) | 2006-12-10 |
ATE504600T1 (de) | 2011-04-15 |
JP2007532482A (ja) | 2007-11-15 |
WO2005080972A1 (en) | 2005-09-01 |
MXPA06009518A (es) | 2007-03-23 |
EP1721157B1 (de) | 2011-04-06 |
CA2558770A1 (en) | 2005-09-01 |
ZA200606840B (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005027322D1 (de) | Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall | |
ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
CY1122238T1 (el) | Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων | |
DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
DE602005015862D1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
DE602005026169D1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
CY1105880T1 (el) | Χρηση μιας φαρμακευτικης συνθεσεως πepιεχουσης γαλακτικο οξυ ή γαλακτικη ριζα και καλιο για την αγωγη του εγκεφαλικου οιδηματος ή του τραυματισμου του εγκεφαλου | |
NO20055741L (no) | Nye kjemiske forbindelser | |
MA30392B1 (fr) | Composes organiques et leurs utilisations | |
ATE309543T1 (de) | Natürlicher ligand von gpcr chemr23 und dessen verwendung | |
ATE439831T1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
FI20060246A0 (fi) | Uusi kasvua stimuloiva proteiini ja sen käyttö | |
MXPA05009743A (es) | Composiciones con actividad hematopoyetica e inmune. | |
ATE432275T1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
ATE396982T1 (de) | Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors | |
EA200601220A1 (ru) | Анти-trkc антитела-агонисты и способы их применения | |
ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
DE60325496D1 (de) | Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden | |
ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen | |
ATE490269T1 (de) | Kristallstruktur der trypanosoma cruzi proline racemase (tcpraca) und verwendung davon |